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expected number of cases of meningococcal meningitis in a devel-
oping country (Kenya). METHODS: We constructed a simula-
tion model of the spread of meningitis and the effects of
intervention strategies with data from peer-reviewed literature.
The effectiveness of each intervention strategy was measured in
terms of the expected annual number of cases of meningococcal
meningitis prevented, relative to a “do nothing” strategy. Each
person in a population of 10,000 was modeled daily as a distinct
entity with an array of personal and demographic attributes. This
approach captured the population heterogeneity and allowed
modeling person-to-person interactions. Modeling population
members as distinct entities also allowed us to direct intervention
strategies toward at-risk individuals. Simulations using 100 dif-
ferent seeds, representing unique starting years were performed.
Intervention strategies were: 1) vaccinating 6-year olds entering
school; 2) vaccinating persons ages three to ﬁfteen years (the
most at-risk population); and 3) providing chemoprophylaxis
(antibiotics for short term protection against invasive cases of the
disease) to family members of meningococcal meningitis patients.
Vaccination provides protection for a speciﬁed period of time
(2 years by default), while chemoprophylaxis is protecting only
during the course of the drug. A force-of-infection function rep-
resenting the probability that a person exposed to a carrier
becomes infected allows modeling of seasonal variation.
RESULTS: Average annual number of cases without treatment
was 29.54. Strategy 1 reduced expected annual cases by 4.91
(p < 0.01), strategy 2 by 16.91 (p < 0.01), and strategy 3 by 1.21
(NS). CONCLUSIONS: The strategy of vaccinating only six-
year-old children and the strategy of vaccinating persons ages
three to ﬁfteen years both signiﬁcantly reduced the number of
invasive cases. The strategy of giving chemoprophylaxis to family
members of meningococcal meningitis patients did not signiﬁ-
cantly reduce the number of invasive cases.
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OBJECTIVES: HCV patients with ALT-N have a slower pro-
gression to cirrhosis than patients with elevated transaminases
(ALT-E). The use and impact of treatment on HCV progression
are controversial in this population. We estimated the impact of
antiviral treatment on the morbidity and mortality in patients
with ALT-N, comparing with ALT-E, following different sce-
narios of treatment. METHODS: A Markov model of CHC
with a twenty-year time horizon (2006–2025) was adapted to
simulate ALT-N patients (30%) and ALT-E patients (70%)
separately. The model takes into account: 1) The faster ﬁbrosis
progression rates for higher age, males and ALT-E; 2) The
improvement of HCV screening and treatment; 3) The competi-
tive mortality. The model is calibrated on reported HCC mor-
tality (CepiDc). Antiviral treatment effects were incorporated
by estimating the likelihood of being screened for HCV (InVS),
of being treated (GERS) and of becoming sustained viral
responders (literature review). We assumed that patients with
ALT-N are treated 80% lower between 2002 and 2004 and
70% lower from 2005 than the ALT-E (HEPATYS). A sensitiv-
ity analysis has been assessed. RESULTS: The model showed
that the antiviral treatment reduced by 36,000 cirrhosis (35%),
23,100 cirrhosis complications (26%) and 18,000 deaths
(23%) on the total HCV population, including 3,000 cirrhosis
(20%), 1,200 complications (14%) and 1,000 deaths (13%) in
the ALT-N population, despite a probability to be treated 3 to
5 times lower in this population. Moreover, if ALT-N patients
are treated in the same proportions than ALT-E, morbidity and
mortality could be further reduced by 1,400 cirrhosis (12%),
600 complications (9%) and 500 deaths (8%). CONCLU-
SIONS: The treatment of CHC patients with ALT-N should
have a long-term impact on morbidity and mortality, less
important than in ALT-E patients. The sensitivity analysis
showed that the proportion of ALT-N is the parameter having
the most inﬂuence on the results.
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OBJECTIVES: To assess the impact of mass vaccination with
Priorix-Tetra™ (GlaxoSmithKline Biologicals’ MMRV; measles,
mumps, rubella, varicella) vaccine versus Priorix™ (GlaxoSmith-
Kline Biologicals’ MMR; measles, mumps, rubella) vaccine on
the epidemiology of varicella and zoster. Sustained high coverage
with MMRV is possible by replacing MMR. Vaccination can
cause an age shift in varicella incidence, and could conceivably
increase zoster incidence by removing the trigger for internal
boosting of immunity to zoster. METHODS: A dynamic trans-
mission model was developed, accounting for the natural history
of varicella and zoster, virus transmission, interactions between
varicella and zoster (boosting effects), and age-speciﬁc contact
rates. The model used peer-reviewed French data. Scenarios were
run to evaluate uncertainty in contact patterns within and
between age groups. RESULTS: Following the introduction of
MMRV, varicella incidence was signiﬁcantly reduced from
12,571 to 4,859/million person-years at the post-vaccination
equilibrium (after around 30 years). All evaluated contact pat-
terns predicted large decreases in disease incidence. Zoster inci-
dence increased slightly in the ﬁrst 20 years post-vaccination (e.g.
1860 to 1918/million-person-years in people aged >50 years).
This then declined as the vaccinated cohort aged, due to the
assumed lower viral reactivation rate with the vaccine. Before
vaccination, the highest incidence of varicella was in the 2–4 year
olds, but this shifted to the 5–11 year age group (pre-vaccination
incidence 2373 versus 3535/million person-years after MMRV).
Neither the short term increase in zoster cases nor the age shift to
5–11 year olds were projected to have a signiﬁcant impact on the
burden of the disease. By 80 years post-vaccination, the incidence
of zoster had decreased from 3242 to 1326/million person-years
and was still decreasing as the vaccinated cohort aged. CON-
CLUSIONS: Replacement of Priorix™ with Priorix-Tetra™
allows sustained mass vaccination against varicella which is pre-
dicted to signiﬁcantly reduce varicella, and eventually zoster,
incidence and disease burden.
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